Abstract: Die stacks and methods of making die stacks with very thin dies are disclosed. The die surfaces remain flat within a 5 micron tolerance despite the thinness of the die and the process steps of making the die stack. A residual flux height is kept below 50% of the spacing distance between adjacent surfaces or structures, e.g. in the inter-die spacing.

Abstract: The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed herein allows nitenin and nitenin analogue compounds to act as analgesic through reduction of K30 currents rather than their potentiation. Related to their high efficacy in the treatment of pain, these compounds are highly selective for slow voltage-activated potassium (K30 ) currents expressed in the small diameter dorsal root neurons (sDRGns), mainly on those mediated by the voltage-dependent potassium channel (KV), KV1.3. Such findings, together with those showing that nitenin and nitenin analogue compounds act as activity dependent blockers also lead to very reduced side-effects.

Abstract: The present patent application relates to the use of antagonists of delayed rectifier potassium (K+) channels, more specifically Kv1.3 antagonists, as pharmaceutical agents in the treatment, prevention or reduction of both acute and chronic pain. The results and mode of action disclosed herein describe how Kv1.3 antagonists may act as analgesics through reduction of K+ currents rather than their potentiation. With regard to their high efficacy in the treatment of pain, these compounds are highly selective for slow delayed rectifier voltage-activated potassium (K+) currents. Such findings, together with those showing that nitenin, PSORA-4, PAP-1 and AM92016 hydrochloride act as K+ channel blockers and by their effects on K+ current inactivation profiles, also translate into an analgesic effect with reduced side effects. The results disclosed herein show that compounds that inhibit delayed rectifying Kv1.

Abstract: The present disclosure describes a eutectic composition for use in the treatment of cancer comprising a nonsteroidal anti-inflammatory drug and a terpene, preferably ibuprofen and limonene.

Abstract: The present disclosure relates to cryoprotectant and/or cryopreservant composition, methods and uses thereof. This composition may be used in the preservation and/or protection of cell, organism and/or tissue.

Abstract: The present invention relates to a construction method for playground surfacing. The method of the present invention comprises the steps of: a) preparing in situ a mixture comprising 29-70% by weight of cork granules and 30-71% by weight of a polymeric binder, at room temperature; b) pouring the mixture obtained in step a) on at least one surface area; c) compacting said mixture to a thickness in the range of 35-135 mm and to a density in the range of 100-300 kg/m3; and d) curing the compacted mixture from step c).

Abstract: The present disclosure relates to a flexible material which imitates leather, more in particular a textile material, coated with products of vegetable origin. The present disclosure relates to a flexible material comprised of a coated textile substrate, woven, knitted or non-woven fabric, the coating material of which having in its constitution vegetable by-products and residues, which may be of different typologies. In particular, the textiles have residues attached to the textile substrate through the use of a binder. The flexible material of the present disclosure is useful for the textile and confectionery industry and can be extensively applied in the textile industry namely in the manufacture of textile materials for clothing or for application in furniture, home textiles and decoration, footwear, automobile upholstery, bags, wallets, belts, leather goods, etc.

Abstract: Die stacks and methods of making die stacks with very thin dies are disclosed. The die surfaces remain flat within a 5 micron tolerance despite the thinness of the die and the process steps of making the die stack. A residual flux height is kept below 50% of the spacing distance between adjacent surfaces or structures, e.g. in the inter-die spacing.

Abstract: Die stacks and methods of making die stacks with very thin dies are disclosed. The die surfaces remain flat within a 5 micron tolerance despite the thinness of the die and the process steps of making the die stack. A residual flux height is kept below 50% of the spacing distance between adjacent surfaces or structures, e.g. in the inter-die spacing.

Abstract: Die stacks and methods of making die stacks with very thin dies are disclosed. The die surfaces remain flat within a 5 micron tolerance despite the thinness of the die and the process steps of making the die stack. A residual flux height is kept below 50% of the spacing distance between adjacent surfaces or structures, e.g. in the inter-die spacing.

Abstract: The present invention provides a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein an antioxidant compound selected from the group of flavonoids or methoxytryptophols, an ester thereof, a pharmaceutically acceptable salt thereof or a combination thereof, is/are coated to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. This implant is useful for replace bone tissue in vertebrate animals, and furthermore restore the normal function of said tissue, mainly due to its ability of induce osseointegration and soft tissue attachment.

Abstract: The present invention relates to a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein a compound selected from the group consisting of an IP, an ester of an IP, and/or a pharmaceutically acceptable salt thereof, or a combination thereof, is/are covalently bound to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. The covalent bond between the IP and the metal, metal alloy or metal oxide surface can be further assisted by the use of a linker. An implant according to the invention provides for a modulated and/or improved osseointegrative effect when implanted into a body, such as a mammalian body, by virtue of the coating comprising covalently bound phytate.

Abstract: The present invention provides a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein an antioxidant compound selected from the group of flavonoids or methoxytryptophols, an ester thereof, a pharmaceutically acceptable salt thereof or a combination thereof, is/are coated to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. This implant is useful for replace bone tissue in vertebrate animals, and furthermore restore the normal function of said tissue, mainly due to its ability of induce osseointegration and soft tissue attachment.

Abstract: The present invention relates to a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein a compound selected from the group consisting of an IP, an ester of an IP, and/or a pharmaceutically acceptable salt thereof, or a combination thereof, is/are covalently bound to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. The covalent bond between the IP and the metal, metal alloy or metal oxide surface can be further assisted by the use of a linker. An implant according to the invention provides for a modulated and/or improved osseointegrative effect when implanted into a body, such as a mammalian body, by virtue of the coating comprising covalently bound phytate.